Advertisement
Australia markets close in 3 hours 4 minutes
  • ALL ORDS

    8,067.90
    +2.40 (+0.03%)
     
  • ASX 200

    7,794.30
    +1.00 (+0.01%)
     
  • AUD/USD

    0.6573
    -0.0028 (-0.42%)
     
  • OIL

    78.07
    -0.31 (-0.40%)
     
  • GOLD

    2,324.70
    +0.50 (+0.02%)
     
  • Bitcoin AUD

    95,513.21
    -1,371.41 (-1.42%)
     
  • CMC Crypto 200

    1,301.62
    -63.50 (-4.65%)
     
  • AUD/EUR

    0.6118
    -0.0013 (-0.21%)
     
  • AUD/NZD

    1.0975
    -0.0013 (-0.12%)
     
  • NZX 50

    11,795.99
    -4.79 (-0.04%)
     
  • NASDAQ

    18,091.45
    -2.12 (-0.01%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • Dow Jones

    38,884.26
    +31.99 (+0.08%)
     
  • DAX

    18,430.05
    +254.84 (+1.40%)
     
  • Hang Seng

    18,557.45
    +78.08 (+0.42%)
     
  • NIKKEI 225

    38,303.39
    -531.71 (-1.37%)
     

Animalcare Group Full Year 2023 Earnings: EPS: UK£0.02 (vs UK£0.033 in FY 2022)

Animalcare Group (LON:ANCR) Full Year 2023 Results

Key Financial Results

  • Revenue: UK£74.4m (up 3.8% from FY 2022).

  • Net income: UK£1.20m (down 39% from FY 2022).

  • Profit margin: 1.6% (down from 2.7% in FY 2022). The decrease in margin was driven by higher expenses.

  • EPS: UK£0.02 (down from UK£0.033 in FY 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Animalcare Group Earnings Insights

Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Pharmaceuticals industry in the United Kingdom.

Performance of the British Pharmaceuticals industry.

ADVERTISEMENT

The company's shares are up 1.9% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for Animalcare Group (1 is a bit unpleasant!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.